The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Psychopathological symptoms during interferon-α and ribavirin treatment: effects on virologic response
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IFN-alpha is notorious for producing behavioral symptoms including fatigue and neurovegetative symptoms, cognitive and sleep changes, anxiety, and anhedonia, and induces depression in 30–50% of treated-patients depending on the dose (Capuron et al., 2002, Maddock et al., 2005, Raison et al., 2005a, Lotrich, 2009).”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Maddock et al., 2005
In the citing paper
“therapeutic administration of the cytokine interferon-alpha (IFN-alpha) leads to a depressive symptomatology in up to 50% of patients, who show similar biological alterations as those found in MD and can be treated with antidepressant medication”
From Glucocorticoids, cytokines and brain abnormalities in depression (2011) · cites this paper as Maddock et al., 2005
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Development of a fatigue scale
Chalder, T., Berelowitz, G., Pawlikowska, T., Watts, L., Wessely, S., Wright, D., & Wallace, E. P. (1993) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(93)90081-p · Cited by 3,032
Measuring Functioning and Well-Being: The Medical Outcomes Study Approach
Stewart, A., & Ware, J. (1992) · doi:10.7249/cb361 · Cited by 2,689
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders
Pariante, C. M., Orrù, M. G., Baita, A., Farci, M. G., & Carpiniello, B. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04793-x · Cited by 165
Self-citationRaison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.05.001 · Cited by 131
Maddock, C., Baita, A., Orrù, M. G., Sitzia, R., Costa, A., Muntoni, E., Farci, M. G., Carpiniello, B., & Pariante, C. M. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104040230 · Cited by 89
Self-citationLoftis, J. M., Socherman, R., Howell, C. D., Whitehead, A. J., Hill, J., Dominitz, J. A., & Hauser, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.04.058 · Cited by 62
Interferon Alfa–Induced Adverse Effects in Patients with a Psychiatric Diagnosis
Pariante, C. M., Landau, S., & Carpiniello, B. (2002) · New England Journal of Medicine · doi:10.1056/nejm200207113470221 · Cited by 59
Self-citation
Cited by
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
“…for producing behavioral symptoms including fatigue and neurovegetative symptoms, cognitive and sleep changes, anxiety, and anhedonia, and induces depression in 30–50% of treated-patients depending on the dose (Capuron et al., 2002, Maddock et al., 2005, Raison et al., 2005a, Lotrich, 2009).”
BackgroundGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
“…(IFN-alpha) leads to a depressive symptomatology in up to 50% of patients, who show similar biological alterations as those found in MD and can be treated with antidepressant medication (Capuron and Miller, 2004; Raison et al., 2005; Maddock et al., 2005; Lotrich et al., 2007; Bull et al., 2009).”
BackgroundSelf-citationCapuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., Votaw, J. R., Goodman, M. M., & Miller, A. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2094 · Cited by 382
Zunszain, P. A., Hepgul, N., & Pariante, C. M. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_211 · Cited by 303
Self-citationBasal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301362 · Cited by 229
“…a mood/cognitive syndrome, including depressed mood, anxiety, and attentional and memory alterations, and a neurovegetative syndrome, including fatigue (the most common IFN-a-induced symptom), anorexia, psychomotor slowing, and sleep disturbances (Capuron et al, 2002a; Maddock et al, 2005).”
BackgroundInfluentialBull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Self-citationThe glucocorticoid receptor: part of the solution or part of the problem?
Pariante, C. M. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806066063 · Cited by 192
“In turn, treatment with proinflammatory cytokines, or treatments that increase the production of pro-inflammatory cytokines like interferon-alpha, can induce depressive symptoms (Pariante et al., 1999a; Pariante et al., 2002a; Raison and Miller, 2003a, b; Maddock et al., 2004; Maddock et al., 2005).”
BackgroundSelf-citationRaison, C. L., Borisov, A. S., Woolwine, B. J., Massung, B., Vogt, G., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.58 · Cited by 183
The effects of HCV infection and management on health-related quality of life
Younossi, Z., Kallman, J., & Kincaid, J. (2007) · Hepatology · doi:10.1002/hep.21565 · Cited by 173
Su, K.-P., Huang, S.-Y., Peng, C.-Y., Lai, H.-C., Huang, C.-L., Chen, Y.-C., Aitchison, K. J., & Pariante, C. M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.005 · Cited by 165
“In turn, these symptoms result in poor compliance or discontinuation of IFN-α treatment and in poor viral response (4,5).”
BackgroundSelf-citationGlucocorticoid Dysregulations and Their Clinical Correlates: From Receptors to Therapeutics
Marques, A. H., Silverman, M. N., & Sternberg, E. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04987.x · Cited by 158
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
The Immune System and the Role of Inflammation in Perinatal Depression
Leff, P., Mancilla‐Herrera, I., Flores‐Ramos, M., Cruz-Fuentes, C. S., Reyes‐Grajeda, J. P., García-Cuétara, M. D. P., Bugnot-Pérez, M. D., & Pulido-Ascencio, D. E. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0048-3 · Cited by 139
Majer, M., Welberg, L. A. M., Capuron, L., Pagnoni, G., Raison, C. L., & Miller, A. H. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.12.009 · Cited by 124
“…depressed mood, anhedonia, anergia/fatigue, psychomotor slowing, cognitive dysfunction, anxiety/irritability, anorexia, sleep alterations and increased sensitivity to pain (Loftis and Hauser, 2004; Maddock et al., 2005; Reichenberg et al., 2005; Asnis and De La Garza, 2006; Lotrich et al., 2007).”
BackgroundAssociation of peripheral inflammatory markers with chronic fatigue in a population-based sample
Raison, C. L., Lin, J.-M. S., & Reeves, W. C. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.11.005 · Cited by 114
“Moreover, chronic cytokine exposure, such as occurs during treatment with interferon-alpha, frequently leads to severe fatigue and other symptoms common in CFS (Capuron et al., 2002; Maddock et al., 2005), demonstrating that innate immune cytokines are capable of producing a CFS-like clinical picture.”
BackgroundRussell, A., Hepgul, N., Nikkheslat, N., Borsini, A., Zajkowska, Z., Moll, N., Forton, D., Agarwal, K., Chalder, T., Mondelli, V., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.11.032 · Cited by 83
“This lower KYN/ TRP ratio in CFS (and the lack of association with PF) is somewhat in opposition to a study of somatization which observed higher levels of the KYN/TRP ratio (Maes et al., 2011).”
Self-citationMehta, D., Raison, C. L., Woolwine, B. J., Haroon, E., Binder, E. B., Miller, A. H., & Felger, J. C. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.004 · Cited by 74
“Administration of inflammatory cytokines such as interferon (IFN)-alpha or inflammatory stimuli such as typhoid vaccination or endotoxin have also been shown to induce depressive symptoms (Capuron et al., 2002; Eisenberger et al., 2010; Harrison et al., 2009; Maddock et al., 2005; Raison et al., 2006; Reichenberg et a…”
BackgroundIn vitro modulation of the glucocorticoid receptor by antidepressants
Carvalho, L. A., & Pariante, C. M. (2008) · Stress · doi:10.1080/10253890701850759 · Cited by 56
“In turn, treatment with proinflammatory cytokines, or treatments that increase the production of pro-inflammatory cytokines like interferon-a for chronic viral hepatitis, can induce depressive symptoms (Pariante et al. 1999, 2002a; Raison and Miller 2003, Maddock et al. 2004, 2005).”
BackgroundSelf-citationSu, K., Lai, H., Peng, C., Su, W., Chang, J. P., & Pariante, C. M. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.04.032 · Cited by 75
“9%, a finding that is consistent with most prospective studies, in which the occurrence rates ranged from 20% to 45% (Beratis et al., 2005; Bonaccorso et al., 2002a,b; Constant et al., 2005; Hauser et al., 2002; Horikawa et al., 2003; Lotrich et al., 2007; Maddock et al., 2005; Miyaoka et al., 1999; Robaeys et al., 20…”
ResultSelf-citationEvon, D. M., Ramcharran, D., Belle, S. H., Terrault, N. A., Fontana, R. J., & Fried, M. W. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.528 · Cited by 68
Castéra, L., Constant, A., Henry, C., Champbenoît, P., Bernard, P., de Lédinghen, V., Demotes‐Mainard, J., & Couzigou, P. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03107.x · Cited by 57
Alberti, A. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01945.x · Cited by 53
Fontana, R. J., Kronfol, Z., Lindsay, K. L., Bieliauskas, L. A., Padmanabhan, L., Back‐Madruga, C., Lok, A. S.-F., Stoddard, A. M., & the HALT-C Trial Group (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02106.x · Cited by 46
“Previous studies of short-term interferon therapy have demonstrated dramatic changes in the HPA axis in healthy individuals and CHC patients (14, 41, 42).”
BackgroundQuelhas, R., & Lopes, A. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000358313.06858.ea · Cited by 46
N-acetyl-cysteine prevents toxic oxidative effects induced by IFN-α in human neurons
Alboni, S., Gibellini, L., Montanari, C., Benatti, C., Benatti, S., Tascedda, F., Brunello, N., Cossarizza, A., & Pariante, C. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000266 · Cited by 35
“IFN-α-induced psychiatric symptoms not only strongly affect patient’s quality of life but may also significantly compromise therapeutic response (Maddock et al., 2005; Leutscher et al., 2010).”
BackgroundSelf-citationLotrich, F. E., Loftis, J. M., Ferrell, R. E., Rabinovitz, M., & Hauser, P. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0074 · Cited by 35
Risk factors for the development of depression in patients with hepatitis C taking interferon-α
Smith, K. J., Norris, S., O’Farrelly, C., & O’Mara, S. M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13917 · Cited by 39
“42,43 44–47 Three main mechanisms that are supported by clinical data are introduced briefly before clinical data assessing their relationship with depression is discussed.”
Munshi, S., & Rosenkranz, J. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.08.017 · Cited by 36
“In addition, interferon (IFN)-α used in treatment of some viral infections and cancers increases peripheral IL-6 and (TNF)-α and induces symptoms of depression (Capuron et al., 2002; Maddock et al., 2005; Raison et al., 2005).”
BackgroundCooper, C. M., Godlewska, B., Sharpley, A. L., Barnes, E., Cowen, P. J., & Harmer, C. J. (2018) · Psychological Medicine · doi:10.1017/s0033291717002379 · Cited by 20
“IFN-α significantly increased depression severity ratings, as well as subjective ratings of state anxiety and fatigue by 6–8 weeks, which is in keeping with numerous previous reports of induction of depressive symptoms by this treatment (Musselman et al. 2001; Hauser et al. 2002; Schaefer et al. 2002; Capuron & Miller…”
ResultEvon, D. M., VERMA, A., SIMPSON, K., Galanko, J. A., Dougherty, K. A., & FRIED, M. W. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03640.x · Cited by 19
Al-Huthail, Y. R. (2006) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.27847 · Cited by 18
Schäfer, A., Scheurlen, M., Weißbrich, B., Schöttker, K., & Kraus, M. R. (2007) · Chemotherapy · doi:10.1159/000102584 · Cited by 16
An extended concept of altered self: Chronic fatigue and post-infection syndromes
Jones, J. F. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.11.007 · Cited by 19
“, 2006), such as sleepiness, loss of appetite, cognitive problems, and long-lasting fatigue, occur later in the course of treatment with these biologic response modifiers and may persist or increase in magnitude over the duration of therapy (Wichers and Maes, 2002; Maddock et al., 2005).”
BackgroundNeuropsychiatric Symptoms of Hepatitis C
Saunders, J. C. (2008) · Issues in Mental Health Nursing · doi:10.1080/01612840701869239 · Cited by 20
“A reduction in quality of life was found to be associated with fatigue in HCV patients on interferon, rather than depression or anxiety (Maddock et al., 2005).”
BackgroundHou, X.-J., Xu, J., Wang, J., & Yu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076799 · Cited by 14
“Furthermore, depressive symptoms are closely related to poor virological response [19,20].”
BackgroundShakoor, A., Shafqat, F., Mehmud, T. E. H., Akram, M., Riaz, S., Iqbal, Z., & Khan, A. A. (2010) · PubMed · Cited by 15
Role of the nurse practitioner in the management of patients with chronic hepatitis C
Olson, M., & Jacobson, I. M. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2011.00603.x · Cited by 11
“Interestingly, it has been suggested that patients with more severe symptoms of depression may be less likely to attain SVR (Maddock et al., 2005; Raison et al., 2005b).”
BackgroundOrrù, M. G., Baita, A., Sitzia, R., Costa, A., Muntoni, E., Landau, S., Chessa, L., Farci, M. G., Carpiniello, B., & Pariante, C. M. (2005) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00006394 · Cited by 12
Self-citationHuang, Y., Hu, J., Hu, F., Chang, C., Chang, H.-Y., Kao, J., Yang, S.-S., & Chen, D. (2012) · Antiviral Therapy · doi:10.3851/imp2441 · Cited by 9
“Depression has also been associated with poorer treatment response independent of dose reduction [7,8].”
BackgroundSims, O. T., Whalen, C. C., Nackerud, L. G., & Bride, B. E. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182a47397 · Cited by 8
Reimer, J., Backmund, M., & Haasen, C. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000186812.01202.a5 · Cited by 7
The Role of Immune System in Depression Disorder
Hoseinzadeh, F., Abadi, P. H., Agheltar, M., Aghayinejad, A., Torabian, F., Rezayat, A. A., Akbarzadeh, F., & Rahimi, H. R. (2016) · Health · doi:10.4236/health.2016.815167 · Cited by 6
Periche-Tomas, E., Cattaneo, A., Cattane, N., Bone, C., Tibble, J. A., Bullmore, E. T., Pariante, C. M., & Harrison, N. A. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.09.038 · Cited by 5
“Though clinically effective, chronic IFN-α administration frequently induces severe sickness responses, including functionally impairing fatigue and major depressive episodes (Capuron et al., 2002; Capuron & Miller, 2004; Maddock et al., 2005).”
Self-citationUğurlu, G. K., Ugurlu, M. M., & Çayköylü, A. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312467346 · Cited by 4
“In some case reports, where ribavirin was used in conjunction with other agents such as interferon-alpha, it has been reported that psychiatric side effects occurred, including depression, fatigue, anxiety symptoms, cognitive impairment and a decrease in quality of life [Maddock et al. 2005; Abdel-Salam, 2006].”
BackgroundPawłowski, T., Radkowski, M., Perlejewski, K., Laskus, T., & Małyszczak, K. (2024) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001274 · Cited by 3
Chronic hepatitis from a psychiatric point of view
Özdemir, S. (2008) · Cited by 3
Elsayed, H., Elsayed, M., Arafa, M., & El‐Bendary, M. (2012) · Middle East Current Psychiatry · doi:10.1097/01.xme.0000407891.12614.d0 · Cited by 2
Nakagawa, R., Nakashima, H., Sato, M., Nagamine, M., Kinoshita, M., Asai, F., Yoshino, A., Toda, H., & Koga, M. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149787 · Cited by 2
Depressive symptoms and viral clearance: In response
Raison, C. L., Capuron, L., & Miller, A. H. (2005) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2005.03.006 · Cited by 2
Depression and antiviral response to interferon-based therapy for hepatitis C virus infection
Loftis, J. M., Morasco, B. J., & Hauser, P. (2010) · Hepatology · doi:10.1002/hep.24064 · Cited by 2
van Hoek, B. (2006) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8808-0_859
Immune dysregulation in bipolar disorder
Teixeira, A. L., Barbosa, I. G., & Bauer, M. E. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107477278.022 · Cited by 1
New Referral Hepatitis C Protocol: The New Standard
Redden, T. L. (2014) · NDSU Repository (North Dakota State University)
Current awareness: Pharmacoepidemiology and drug safety
(2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1032
Metadata
- Authors
- Maddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., Norris, S., & Pariante, C. M.
- Affiliations
- Maudsley Hospital (GB)
- King's College London (GB)
- Corresponding author
- Pariante, C M
- Venue
- Molecular Psychiatry
- Published
- 2005-01-18
- Volume
- 10
- Issue
- 4
- Pages
- 332-333
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2015033812
- Cited by
- 54
- References
- 10
- Citations by year
- 2025: 1 · 2024: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2014: 1 · 2013: 5 · 2012: 5
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- interferon-alpha, ribavirin, psychiatric symptoms, depression, anxiety, virological response, chronic hepatitis C, antiviral therapy
- MeSH terms
- Interferon alpha-2, Adult, Antiviral Agents, Anxiety, Depression, Drug Carriers, Drug Therapy, Combination, Fatigue, Female, Humans, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Ribavirin, Severity of Illness Index, Time Factors, Treatment Outcome, Interferon-alpha, Hepatitis C, Chronic, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.